Marisi et al. reported through a multicentric retrospective study which included 135 HCC patients, all receiving sorafenib, that ANGPT2 rs55633437 TT/GT genotypes were accompanied by a lower median OS and PFS than did patients with other genotypes. Here, ANGPT2 is linked to hepatocellular carcinoma.